Literature DB >> 19133231

Constitutively active erythropoietin receptor expression in breast cancer cells promotes cellular proliferation and migration through a MAP-kinase dependent pathway.

Ping Fu1, Xiaohong Jiang, Murat O Arcasoy.   

Abstract

The role of erythropoietin receptor (EpoR) expression in tumor cells and the potential of EpoR-mediated signaling to contribute to cellular proliferation and invasiveness require further characterization. To determine whether EpoR expression and activation in tumor cells modulates intracellular signal transduction to promote cellular proliferation and migration, we employed a novel experimental model using human breast cancer cells engineered to stably express a constitutively active EpoR-R129C variant. EpoR-R129C expression resulted in increased cellular proliferation and migration of breast cancer cells and these effects were associated with significantly increased Epo-induced phosphorylation of ERK1/2, AKT and c-Jun-NH2-kinase (SAPK/JNK) proteins. Expression of the constitutively active EpoR-R129C receptor promoted the proliferation and migration of breast cancer cells via activation of ERK- and SAPK/JNK-dependent signaling pathways, respectively. These findings suggest that EpoR over-expression and activation in breast cancer cells has the potential to contribute to tumor progression by promoting the proliferation and invasiveness of the neoplastic cells.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19133231      PMCID: PMC2666149          DOI: 10.1016/j.bbrc.2008.12.146

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  36 in total

1.  Weighing the hazards of erythropoiesis stimulation in patients with cancer.

Authors:  Fadlo R Khuri
Journal:  N Engl J Med       Date:  2007-06-14       Impact factor: 91.245

2.  Erythropoietin inhibits apoptosis in breast cancer cells via an Akt-dependent pathway without modulating in vivo chemosensitivity.

Authors:  Matthew E Hardee; Zahid N Rabbani; Murat O Arcasoy; John P Kirkpatrick; Zeljko Vujaskovic; Mark W Dewhirst; Kimberly L Blackwell
Journal:  Mol Cancer Ther       Date:  2006-02       Impact factor: 6.261

3.  Erythropoietin stimulates proliferation of human renal carcinoma cells.

Authors:  C Westenfelder; R L Baranowski
Journal:  Kidney Int       Date:  2000-08       Impact factor: 10.612

4.  Erythropoietin fails to interfere with the antiproliferative and cytotoxic effects of antitumor drugs.

Authors:  David A Gewirtz; Xu Di; Teneille D Walker; Stephen T Sawyer
Journal:  Clin Cancer Res       Date:  2006-04-01       Impact factor: 12.531

5.  Antiapoptotic effects of erythropoietin in differentiated neuroblastoma SH-SY5Y cells require activation of both the STAT5 and AKT signaling pathways.

Authors:  Moonkyoung Um; Harvey F Lodish
Journal:  J Biol Chem       Date:  2006-01-04       Impact factor: 5.157

Review 6.  Erythropoiesis-stimulating agent use in cancer: preclinical and clinical perspectives.

Authors:  Murat O Arcasoy
Journal:  Clin Cancer Res       Date:  2008-08-01       Impact factor: 12.531

7.  Erythropoietin treatment of human ovarian cancer cells results in enhanced signaling and a paclitaxel-resistant phenotype.

Authors:  Peter Solar; Laurie Feldman; Jee-Yeong Jeong; Jacqueline R Busingye; Arthur J Sytkowski
Journal:  Int J Cancer       Date:  2008-01-15       Impact factor: 7.396

Review 8.  Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia.

Authors:  Charles L Bennett; Samuel M Silver; Benjamin Djulbegovic; Athena T Samaras; C Anthony Blau; Kara J Gleason; Sara E Barnato; Kathleen M Elverman; D Mark Courtney; June M McKoy; Beatrice J Edwards; Cara C Tigue; Dennis W Raisch; Paul R Yarnold; David A Dorr; Timothy M Kuzel; Martin S Tallman; Steven M Trifilio; Dennis P West; Stephen Y Lai; Michael Henke
Journal:  JAMA       Date:  2008-02-27       Impact factor: 56.272

Review 9.  The non-haematopoietic biological effects of erythropoietin.

Authors:  Murat O Arcasoy
Journal:  Br J Haematol       Date:  2008-04       Impact factor: 6.998

10.  Erythropoietin blockade inhibits the induction of tumor angiogenesis and progression.

Authors:  Matthew E Hardee; Yiting Cao; Ping Fu; Xiaohong Jiang; Yulin Zhao; Zahid N Rabbani; Zeljko Vujaskovic; Mark W Dewhirst; Murat O Arcasoy
Journal:  PLoS One       Date:  2007-06-20       Impact factor: 3.240

View more
  13 in total

Review 1.  Erythropoietin receptor response circuits.

Authors:  Don M Wojchowski; Pradeep Sathyanarayana; Arvind Dev
Journal:  Curr Opin Hematol       Date:  2010-05       Impact factor: 3.284

2.  Erythropoietin-driven proliferation of cells with mutations in the tumor suppressor gene TSC2.

Authors:  Yoshihiko Ikeda; Angelo M Taveira-DaSilva; Gustavo Pacheco-Rodriguez; Wendy K Steagall; Souheil El-Chemaly; Bernadette R Gochuico; Rose M May; Olanda M Hathaway; Shaowei Li; Ji-an Wang; Thomas N Darling; Mario Stylianou; Joel Moss
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2010-10-29       Impact factor: 5.464

Review 3.  Promises and pitfalls in erythopoietin-mediated tissue protection: are nonerythropoietic derivatives a way forward?

Authors:  Carla Cerami Hand; Michael Brines
Journal:  J Investig Med       Date:  2011-10       Impact factor: 2.895

4.  Role of erythropoietin receptor signaling in parvovirus B19 replication in human erythroid progenitor cells.

Authors:  Aaron Yun Chen; Wuxiang Guan; Sai Lou; Zhengwen Liu; Steve Kleiboeker; Jianming Qiu
Journal:  J Virol       Date:  2010-09-22       Impact factor: 5.103

5.  Evaluating erythropoietin-associated tumor progression using archival tissues from a phase III clinical trial.

Authors:  Chris P Miller; Kimberly A Lowe; Karine Valliant-Saunders; Joringel F Kaiser; Dominik Mattern; Nicole Urban; Michael Henke; C Anthony Blau
Journal:  Stem Cells       Date:  2009-09       Impact factor: 6.277

6.  Erythropoietin receptor contributes to melanoma cell survival in vivo.

Authors:  S M Kumar; G Zhang; B C Bastian; M O Arcasoy; P Karande; A Pushparajan; G Acs; X Xu
Journal:  Oncogene       Date:  2011-08-22       Impact factor: 9.867

7.  The effect of erythropoietin on normal and neoplastic cells.

Authors:  Steve Elliott; Angus M Sinclair
Journal:  Biologics       Date:  2012-06-27

8.  Erythropoietin-driven signalling and cell migration mediated by polyADP-ribosylation.

Authors:  D Inbar; M Cohen-Armon; D Neumann
Journal:  Br J Cancer       Date:  2012-09-06       Impact factor: 7.640

9.  Epo receptors are not detectable in primary human tumor tissue samples.

Authors:  Steve Elliott; Susan Swift; Leigh Busse; Sheila Scully; Gwyneth Van; John Rossi; Carol Johnson
Journal:  PLoS One       Date:  2013-07-04       Impact factor: 3.240

10.  Methylation of the first exon in the erythropoietin receptor gene does not correlate with its mRNA and protein level in cancer cells.

Authors:  Barbora Fecková; Patrícia Kimáková; Lenka Ilkovičová; Erika Szentpéteriová; Mária Macejová; Ján Košuth; Anthony Zulli; Nataša Debeljak; Petra Hudler; Karin Jašek; Ivana Kašubová; Peter Kubatka; Peter Solár
Journal:  BMC Genet       Date:  2019-01-03       Impact factor: 2.797

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.